ERBB2 and neoplasm: To investigate whether Bp-Bs also has a more potent anti-tumor activity than Bi-Bs or monovalent anti-Her2 bispecific antibody CD3-S-Fab,13 the mice were treated with Bp-Bs, Bi-Bs, or CD3-S-Fab at 1.5 mg/kg every 3 days.